<SEC-DOCUMENT>0001075880-12-000067.txt : 20121002
<SEC-HEADER>0001075880-12-000067.hdr.sgml : 20121002
<ACCEPTANCE-DATETIME>20121002081038
ACCESSION NUMBER:		0001075880-12-000067
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20121002
FILED AS OF DATE:		20121002
DATE AS OF CHANGE:		20121002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		121121562

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20121002.htm
<DESCRIPTION>FORM 6K 2012 10 02
<TEXT>
<html>
<head>
    <title>form6k20121002.htm</title>
    <!--Licensed to: Novogen Laboratories-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="TEXT-INDENT: 0pt; DISPLAY: inline; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5%; FONT-SIZE: 14pt; MARGIN-RIGHT: 5%">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 36pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 36pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">______________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">For the month of October, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Commission File Number <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">________________</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 36pt; FONT-WEIGHT: bold">Novogen Limited</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">140 Wicks Road, North Ryde, NSW, Australia</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive office)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">___________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Form 20-F <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Form 40-F <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Note: Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule lO1(b)(7): <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Note: Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">o</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>No <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf </font>by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Novogen Limited</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">(Registrant)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">/s/&#160;&#160;Ron Erratt</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Ronald Lea Erratt</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Company Secretary</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Date 2 October, 2012</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: right">
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><img src="novogenlogo.jpg" alt=""></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">ASX &amp; MEDIA RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">2 OCTOBER, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">MEI PHARMA ISSUED EUROPEAN PATENT FOR LEAD MITOCHONDRIAL INHIBITOR DRUG CANDIDATE ME-344</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Novogen Limited&#8217;s subsidiary, Marshall Edwards, Inc., (NASDAQ: MEIP), has made the following announcement:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">San Diego &#8211; 2 October, 2012 &#8211; MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that the European Patent Office has issued a new patent, European Patent No. 1 794 141 B1, covering the pharmaceutical composition of the company&#8217;s lead mitochondrial inhibitor candidate, ME-344, and its use in treating cancer.&#160;&#160;The patent is expected to provide protection until September, 2025.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">&#8220;This key European patent further reinforces the intellectual property protection surrounding our portfolio of oncology drug candidates,&#8221; said Daniel P Gold, PhD, President and Chief Executive Officer of MEI Pharma.&#160;&#160;&#8220;While we continue to execute our Phase I clinical trial for ME-344 and prepare for our upcoming Phase II trials, we believe a strong patent estate will help to provide a clear development path forward and enhance our partnering efforts in the US and abroad."</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">MEI Pharma owns exclusive worldwide rights to all of its drug candidates, including ME-143,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">ME-344 and Pracinostat.&#160;&#160;The company&#8217;s intellectual property portfolio now includes 18 issued US patents and more than 150 issued foreign patents.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">About MEI Pharma</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">MEI Pharma, Inc. is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.&#160;&#160;The company&#8217;s clinical development pipeline includes two isoflavone-based drug candidates derived from its proprietary technology platform, ME-143 and ME-344, and a potential best-in-class, oral histone deacetylase (HDAC) inhibitor, Pracinostat.&#160;&#160;Results from a Phase I dose-escalation trial of lead NADH oxidase inhibitor ME-143 in heavily treated patients with solid refractory tumours were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of lead mitochondrial inhibitor ME-344 in patients with solid refractory tumours is ongoing.&#160;&#160;Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic disorders such as acute myeloid leukemia, myelodysplastic syndrome and myelofibrosis.&#160;&#160;For more information, go to www.meipharma.com.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">About Novogen</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-SIZE: 12pt">Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, MEI Pharma, Inc.&#160;&#160;More information on the Novogen group of companies can be found at </font><font style="DISPLAY: inline; FONT-SIZE: 12pt; TEXT-DECORATION: underline">www.novogen.com</font><font style="DISPLAY: inline; FONT-SIZE: 12pt">.</font></font></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogenlogo.jpg
<TEXT>
begin 644 novogenlogo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!"`,\#`2(``A$!`Q$!_\0`
M'``!`0$!`0`#`0````````````<&!0@!`P0"_\0`1A```0,#`@,&`@4'"`L`
M`````0`"`P0%$08A!Q)!$R(Q46&!%'$(%3*1H187(S1T@K$S.%)RL\'1X4)&
M5%9B=9*3HL+2_\0`&@$!``,!`0$```````````````(#!`$%!O_$`#(1``$#
M`@4"!`4"!P````````$``A$#!!(3(3%!47$%%(&A(C)2D<%AL2,S0D/1X?'_
MV@`,`P$``A$#$0`_`/5*(B(B(B(B(B(B^BKJ8Z5L3I7!H?(V,$]2XX`^_"^]
M8OC#/4TG#ZXU=$XMJ*9\,['#H6RL.?P70),*%1^!A=T"VB+/Z$U12:NT[3W.
MD+0]PY9X0<F*0>+3_$>8(6@0B-"NM<'@.;L41$7%)$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$12'B%Q%O.FM;/H:6*GEM\,<4TC'1DN+3]KO`[;*#WA@DK1;6S[
ME^73W5>1?DM-PI[K;*6OHG\]-41B1A]".OJL;Q8U5<M+TUIDM?89J:GLY.U9
MS=W;PW]5US@T8BH4J+ZM3+;NMZB*8ZLXBUIOCK!HJ@;<KFUQ9)*X]QCAX@#;
M..I)`'JCGANZ[0MWUS#!MOT`_54Y9SB/1FOT%?Z=K>9SJ.1S1ZM;S#\0L74#
MBQ14YJ^VM-86CF=2L8.;'C@;#/EL5VM`:^IM7"HM=RI307B-KFS4S_!X&SN7
M.^W5IW'JN-JC$`=%.M8ORW.:0X<P9A><>'FLJW1E\;64N9*63#*FG)P)69_!
MPZ'_`!*]=V"\45^M%-<K9*):6H;S-/4>;2.A!V(\UXOU/:I+'J&XVR7/-2SN
MC!/4`['W&"J)]'_6#[-J,66KEQ;KB[#`X[1S?Z)'];[)_=\EOK,#AB"^3\-N
MG4:F0_8^Q7IQ$6%L>J+A>>)5WM5*8#9;;&&R.#,N=+L,<W3?FV_X5B+@%]/3
MI.J!Q'`DK=(IQKOB.^UW9MATS0_6E\<>4M`)9&<9Q@;DXW/0=3T7X#'Q9%*:
MKXBTN>!GX4-;S'TSC&?=0-43`U6AMD\M#GD-G:3$JK(I[H'B$^\W*2R:AH?J
MR^1DM[,YY92!D@`^!QOC)SYJA.(:"7$`#<D]%)K@X2%16H/H.PO"(I5=.(MW
MOEVGM?#VV-KG0Y;+6S?R;3G`(W`QL=R=_)?$C.+-,P3MEM%6?$T[6M&/3)`^
M7BH9HX$K1Y%X'QN#3T)U5619_0UQO5SLG;ZDMK;=7-E='V;2>\T>#L;XSOU/
MGU66XA:GU'0:QM5CTTVD=+64YD`G;XN#CUSL,!2+P!B*J9;/?4-,$2)YTT_5
M4E%+^UXK?[/9?^L+>Z:=='62E.H&0,NG*>W;`<LSD^'MA=:Z>%RK0RQ.('L5
MTT46TQQ5N#]7?!7YM.+;+4/I62QQEIC?S$,R<XQMO\\JTKC'A^H7;BUJ6Q`J
M<B418&35=Q;Q?BTV.Q^K7TW:GN=_FY"?'/F%OE(.!V5=2DZG&+D2BC-YH:>Y
M<?Q15L39::>W.CD8[P(,3E9E(I_YQU/^PG^S<JZO'=:;$D%Y'TE?/#6NGTAJ
MNNT5>)3V+W&:W2/.S@23@'U&^/,.7]?2#_4=/_MG_P`KL\8M+R7BRQW:V!S;
MQ:LSPN9]IS1@D#&^1C(]1ZK`\0=3,U9HO3%P#>2H;6]E41_T)!RY]CXCYJI_
MPM+#Z+T;89]9ERW?4.[P=?7]U7^(%TDLNC+O7P9$L4!#"#@ASNZ#[9S[+,<"
M['#;]'Q7-S>:LN)=*Z1P[P9G`;GVSZDK0<3;?)<]!WFF@`,I@[1H]6D.V]=E
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MIIN7]1%0YH.`9.7=H_>V64X602V+AM=-0U>375@FKG.D))(:#RY^9!/NIS8[
MK-=^&%ATG2/'Q%9<WP.V^S&"'[^F7Y_=7H&]6ELND*VTT3.5AHGT\3&[8[F&
MC^"P5!_$,<+ZVU>!9TR_^X03V'^Y^RGW`&SAULKM15K"^X5LSF"5^[N48+CG
MU=G[E6E+^`%U94Z4GMLCP*JBG<3&1@ACMQ\]^8*H+E",`A6>)EWFGAW7VX]E
M(>/EL;1TUMU/1?HJZDG;&Y[-BX>+22/(MQ\B0NOQ6U%)!PPCJ:?FCFNC(HQR
MG!:'MYG;_P!4$>ZY_P!(2XQBP4%FC<365M2U[6MW(:WK[N+0%]O%RQS#A521
MM([6UB%[R/#`;R./_EGV5;Y!?AZ+9;PYMOG;8C';_JU7#6PPZ?T?;Z:)@;-+
M&V>=W5TC@"?NV'LM0L]P_O,%]TC;:N!P+A$V*5N<EDC0`X'W_`A:"0D,<1X@
M%7LC"(V7E7!>:KLS>3*^5)M>5E-;^,^EJJMF9!3QTC^>20X:W)>-S\RNQP7U
M#<]1V"OJ;Q4_$31U;HV'D:WE;R@XV`\UQ.(5NI+MQBTQ0W&!L])-2/#XW9P[
M!>>GJ`J7NQL#AU6^VHY%P^G4X:Z8[<+>MUGIIS@UM]MQ).`!.W_%=]8]G#31
M['M>VQTX<TAP/._8@Y!^TM@KFXOZEAK9.F3/K'X4`T9I>/5>F-9T8:/C&7!T
ME*_P+9!G`SY'P/\`DJ%PAU1)?+));[F[%YMKNPJ&.V<YHV#B#]Q]1ZKB\!?]
M:_\`F)_O7T\1:*HT9K"DUM:8'/II7"&XQ,SN#MS>^W[P!ZJAOP@/'JO3JG/J
M/MG;[M[QMZ_ND_\`..I_V$_V;E75&Z>KAK_I`V^KI7B2GGMPDC<.K3$2%9%9
M2Y[K%>@C+!^D?E%-9;%<W<<X;P*.3ZL;1\AJ-N7FY",?>52D4W-Q0L]*J:4Q
MR"/NB\^<1.']RH-4A^GJ"KJ;75S,J3'`WF;"_F[P(Z#J/0D=%Z#11J4Q4$%7
M6=X^T>7,UGA#N,'P4AO6CM0Z2U#-?-`\L]+.>:HMSSX[Y(`/B/'&.\,E5Y%U
M[`[=5T+AU`G#J#N#L5)GZ]UO5,%-1:(GAK=@Z2;F[,$]=P/XKH\/M!5M#>)=
M1ZKJ6U=\F&0T8+8B1@G/@3C88V`\%2$413UEQE7.O(:64FAH.\;_`'/"+F:E
ML=%J*S5-LN<0DIYFX]6.Z.!Z$+IHK=EA(#A!4%X,:#K[+Q!NLETIY1!;0603
M.9ADSG9`<WS[N3MX9"O2(AU)/5&RUC:?#1`[3/Y4JU;H6[VW4;]3:%F9'6/.
M9Z-Q`$F3EV,[8.,D'KN"OK_.!K7LC3_D+4_'X^WW^S\?+'_LJRBJRX/PF%O%
M[B:!68'1L3,^VZE>C-#7:OU`-3:\E;-<&D.IZ5I!;$1X$XV&.@'4Y.ZJ,\,=
M1!)#.QLD4C2Q['#(<#L05_:*;6!H@*BO</KNQ.XV'`[*-R:0U5H.YS5>B'MN
M%KE)<^AE.X'08SN1T(P?1?K;Q"UC-$Z%FA*OXD=TEW.&Y]V_WJLHH"EA^4PM
M!O14UK,#CUU!]8W4_P""^G;EIS3E5!>*<4\\]296Q\X<0WE`WQ\ER^)-!J"+
MB!9+Y8+0^XBCIG-(R`WF+G9!W'1RJB+N4,(:H>=>:SJY`DSVUT4L_*_B'_N0
MS_O?YK>Z6K;E<+)!47JA%!7.+N>G!SRX)QO\L+K(I!I'*IJ50\0&`=I_RIQP
M<LMRLYU&+G1RTPGKC)$7X[[=]QNMW>+;37BUU5OKH^TIJAAC>WT/4>H\5^Q$
M:T`0E2LZI4S-BH1P\TA>[#Q1IVUE'5OM](R:*.L<W]&6<IY,'IG/AYY5W1%R
MG3#!`5EW=NNGA[QJ!"(B*:RHB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
+B(B(B(B(B(B+_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
